Warfarin-Dose Dx May Not Be Cost-Effective for 'Typical' Patient; May Be for At-Risk Cohort
January 21, 2009
Warfarin-Dose Dx May Not Be Cost-Effective for 'Typical' Patient; May Be for At-Risk Cohort
The meta-analysis comes two weeks before the Centers for Medicare and Medicaid Services is slated to make a national coverage decision regarding PGx-guided warfarin dosing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher Contacted Life Tech in 2011 about Possible Acquisition; Document Discloses Other Bidders
May 22, 2013 / GenomeWeb Daily News - NIH Team Presents Findings from Fungi-focused Study of Skin Microbiome
May 22, 2013 / GenomeWeb Daily News - Mount Sinai, Rensselaer Harness Clinical Medicine, R&D, Computing Synergies
May 22, 2013 / GenomeWeb Daily News - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter - With Exclusive License to Marker, Empire to Launch Neuroendocrine Prostate Cancer Dx This Year
May 22, 2013 / Pharmacogenomics Reporter